Aileron Therapeutics Appoints Experienced Drug Developer, Anthony M. Manning, Ph.D., to Senior Vice President of Research and Preclinical Development

Published: Apr 12, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc., a biopharmaceutical company that has defined a new class of drugs called Stapled Peptides, today announced the appointments of Anthony M. Manning, Ph.D., to senior vice president of research and preclinical development and Yong S. Chang, Ph.D., to head of biology. These strategic appointments come as Aileron continues to advance several drug development programs utilizing its Stapled Peptideā„¢ technology.

Back to news